Toremifene: Fareston®  1st line Metastatic Breast Cancer

• Approved: October 1995

• Trials: 3 randomized Phase 3

• Comparator: Tamoxifen

• Sample size: 1526 patients in all trials

• 1° Endpoints: Response rate, TTP

• Designed to show non-inferiority in RR

Previous slide

Next slide

Back to first slide

View graphic version